Tirzepatide Shows Superior Weight Loss Efficacy Over Oral Semaglutide

Obesity and overweight are significant global health challenges, driving demand for effective pharmacological interventions. Both Tirzepatide (a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist) and oral semaglutide (a GLP-1 receptor agonist) are approved and highly effective for weight management. However, a direct head-to-head comparison of their efficacy and safety specifically for weight loss in a single, randomized clinical trial setting is currently unavailable.

The indirect comparison revealed that Tirzepatide consistently demonstrated superior weight loss efficacy compared to oral semaglutide. Patients treated with Tirzepatide 15 mg achieved an average weight reduction of ~20.9% from baseline, which was substantially higher than the ~6.5% observed with oral semaglutide 14 mg. Tirzepatide 15 mg showed a 3.2-fold greater mean percentage body weight reduction compared to oral semaglutide 14 mg, with this difference being statistically significant (p<0.001). Furthermore, a significantly higher proportion of patients on Tirzepatide 15 mg achieved ≥15% weight loss (~50%) compared to those on oral semaglutide 14 mg (~10%). Both treatments exhibited similar overall safety profiles, predominantly involving mild to moderate gastrointestinal adverse events like nausea and diarrhea, though Tirzepatide at higher doses showed a slightly increased incidence.